Are There Peptide Protocols for Perimenopausal Women?

Perimenopause does not begin with estrogen dropping. That is the part most people get wrong, and it is the reason so many women spend years treating the wrong thing.

Here is the full picture first, because without it, nothing else makes sense.

Your reproductive cycle depends on ovulation. Every time you ovulate, the follicle that releases the egg collapses into something called the corpus luteum, which is a temporary gland that exists for one purpose: producing progesterone in the second half of your cycle. When perimenopause begins, your ovaries stop ovulating consistently, and without ovulation there is no corpus luteum, and without the corpus luteum there is no progesterone. That is the first domino.

Estrogen does not fall with it. This is where the biology gets counterintuitive.

During perimenopause, estrogen becomes erratic. It spikes higher than it ever did in your twenties, then crashes, then spikes again, and this pattern can repeat for years before estrogen finally trends downward into menopause. Research published in the Journal of Clinical Endocrinology and Metabolism by Santoro and colleagues in 2004 documented exactly this pattern, showing that estrogen fluctuates wildly while progesterone declines first and stays low. The result is a broken ratio between the two hormones, and that broken ratio is what is producing most of the symptoms: the disrupted sleep, the anxiety, the visceral fat accumulating around the midsection, the changes in body composition that have nothing to do with diet or training.

So when someone enters perimenopause and the instinct is to add estrogen, that logic skips an important step. Your ovaries are still producing estrogen unpredictably. Adding more on top of an already erratic and sometimes elevated baseline can amplify the imbalance rather than correct it. What is actually deficient is progesterone, and that is what needs to be addressed first.

There is a practical way to know where you stand in this process. Your doctor can measure something called anti-Mullerian hormone, or AMH, which is a marker of how much functional ovarian reserve you have remaining. The Penn Ovarian Aging Study followed 401 women over 14 years and found that AMH levels were strongly predictive of menopause timing, with low or undetectable levels indicating the transition was close. When AMH is essentially undetectable and 12 consecutive months have passed without a period, that is the clinical definition of menopause, and that is the point at which adding estrogen makes sense because the ovaries are no longer producing it unpredictably.

This sequencing matters because it changes what you do at each stage.

In terms of what progesterone replacement actually does for perimenopausal symptoms, a Phase III randomized controlled trial published in 2023 in Scientific Reports by Prior and colleagues found that oral micronized progesterone improved sleep quality and reduced night sweats compared to placebo. Sleep is one of the first things to deteriorate in perimenopause, and the progesterone deficit is a large part of why.

Now, where peptides fit into this picture.

The honest framing is that peptides can manage symptoms that arise from the hormonal disruption, but they are not correcting the hormonal disruption itself. Think of the hormone imbalance as a leak in a pipe and the symptoms as water damage spreading through the house. Peptides can help repair some of the water damage. They do not fix the pipe.

There are three systems where peptides are relevant here.

The first is the metabolic system. The erratic estrogen and low progesterone environment shifts the body toward fat storage, particularly visceral fat, and it increases food-seeking behavior and what is often described as food noise, meaning intrusive and persistent thoughts about eating. Peptides that act on the GLP-1 and GIP receptors, like tirzepatide and retatrutide, work by slowing gastric emptying, increasing satiety signaling, and reducing the central drive to eat. They do not address why the metabolism shifted, but they can meaningfully help manage the consequences.

The second is sleep and anxiety. Peptides like Selank, which is a synthetic analog of a naturally occurring peptide called tuftsin, appear to modulate the GABAergic system in ways that reduce anxiety and support sleep onset. DSIP, or delta sleep-inducing peptide, has been studied for its role in promoting slow-wave sleep specifically. The evidence base here is thinner than for the GLP-1 class of peptides, and much of the research is older or preclinical, so these should be understood as potentially supportive rather than well-established interventions.

The third is the growth hormone axis. This is where something specific and important is happening that most people are not aware of.

Growth hormone secretagogues, peptides like tesamorelin and CJC-1295, work by stimulating the pituitary gland to release more growth hormone, which then drives production of something called IGF-1, a downstream anabolic hormone that supports muscle, recovery, and body composition. The problem is that this system depends on estrogen being present at the pituitary.

A study published in the Journal of Clinical Endocrinology and Metabolism by Shah and colleagues in 2019 measured pulsatile growth hormone secretion in the presence and absence of estradiol and found that pituitary response to growth hormone secretagogues was significantly blunted without estrogen, with a p-value of 0.001. What that means practically is that if you add a growth hormone secretagogue during perimenopause without stabilizing estrogen, you are working against a system that cannot respond the way it should. The peptide is pressing a gas pedal connected to an engine that is not getting fuel.

This is the architecture of how these things interact: hormone foundation first, then peptide support on top of a stable base.

Most discussions about peptides for women in perimenopause start with the peptides. They treat the protocol as the primary intervention and the hormones as a footnote. But the biology runs in the other direction. The growth hormone axis responds to estrogen. Sleep disruption is downstream of progesterone deficiency. Metabolic dysfunction is downstream of the broken ratio between these hormones. The peptides are working on the downstream effects.

Getting the sequence right is not about being conservative or cautious. It is about understanding which layer of the system is actually upstream of the problem you are trying to solve. Fixing something downstream while the upstream driver continues uncorrected is not a protocol. It is just management.

---

References

1. Santoro et al., 2004, Journal of Clinical Endocrinology & Metabolism — progesterone declines before estrogen, estrogen becomes erratic during perimenopause
2. Freeman et al., 2012, Journal of Clinical Endocrinology & Metabolism — AMH predicts menopause timing (Penn Ovarian Aging Study, 401 women, 14 years)
3. Prior, 2014, Facts, Views & Vision in ObGyn — progesterone as appropriate first-line therapy for perimenopause
4. Shah et al., 2019, Journal of Clinical Endocrinology & Metabolism — pulsatile GH secretion significantly blunted without estradiol (P = 0.001), estrogen potentiates pituitary GHRH response
5. Prior et al., 2023, Scientific Reports — Phase III RCT, oral micronized progesterone improved sleep quality and reduced night sweats vs placebo

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness